

Sandwell and West Birmingham Hospitals **MHS Trust**

Switching exenatide or gliptins to liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit

K.Y. Thong¹ • K. Darzy² • M.L. Cull¹ • A.P. Mills¹ • R.E.J. Ryder¹ • ABCD nationwide exenatide and liraglutide audit contributors; ¹City Hospital, Diabetes, Birmingham, UK • ²Queen Elizabeth II Hospital, Diabetes, Welwyn Garden City, UK

International Diabetes Federation 21st World Diabetes Congress, 4–8 December 2011, Dubai, UAE

Introduction

- Results from LEAD-6 and an extension study provide efficacy data comparing patients started on liraglutide 1.8 mg *vs.* exenatide twice daily (BD), as well as the effects of switching exenatide BD to liraglutide 1.8 mg after 26 weeks.
- National guidelines in the UK discourage the use of liraglutide 1.8 mg dose.

3-month weight changes of patients switching exenatide BD or DPP-4 inhibitors to liraglutide 1.2 mg in comparison with liraglutide add-on therapy

	EXE-LIRA switch DPP-4-LIRA switch		DPP-4–LIRA switch	Non-incretin		
¹²⁰ T	p=0.002	ר ¹²⁰ ך	<i>p</i> <0.001	¹²⁰ T	<i>p</i> <0.001	


- In clinical practice, some patients persist with exenatide BD despite gastrointestinal (GI) side-effects or have problems of compliance with two injections.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors, which share a similar mechanism of action with glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA), are mostly stopped when GLP-1RAs are started.

Aims

- To identify whether additional HbA_{1c} and weight benefits are obtained when exenatide BD or DPP-4 inhibitors are switched to liraglutide 1.2 mg (rather than the 1.8 mg dose).
 - Comparison with control group of patients adding liraglutide to non-incretin diabetes treatment.
- To identify whether rates of GI side-effects and liraglutide discontinuation are higher among patients switching from exenatide BD.

Methods

- The ABCD nationwide liraglutide audit:
 - invited diabetes centres across the UK to contribute data on patients started on liraglutide in clinical practice;
 - called for data in 2010 and 2011;
 - had 77 centres participating, registering 4129 patients: currently, 2995 patients have follow-up data.
- Patients were divided into those on exenatide BD, on DPP-4 inhibitor, or not on any incretin-based therapy at the time of liraglutide initiation.
- HbA_{1c} and weight changes, rates of any GI side-effects (nausea, vomiting, diarrhoea) and liraglutide discontinuation were compared between groups at 3 months (taken as \pm 6 weeks for HbA_{1c} and weight data).



Rates of GI side effects and liraglutide discontinuation among patients on exenatide BD, DPP-4 inhibitors or non-incretin therapies

	On exenatide (n=640)	On DPP-4 inhibitors (n=323)	Not on incretin medications (n=2032)	<i>p</i> -value
GI side-effects	10.2%	14.2%	14.1%	0.033
Discontinuation	9.4%	10.2%	7.7%	0.184
GI side-effects	3.3%	3.1%	2.9%	
Lack of efficacy	1.7%	2.8%	1.4%	
Patient choice	1.4%	0.9%	0.2%	
Other reason	3.0%	3.4%	3.2%	

• 135 of 640 patients on exenatide BD provided a reason for switching to liraglutide:

- For HbA_{1c} and weight comparisons, we excluded patients who:
 - were on liraglutide 1.8 mg dose;
 - lacked paired baseline and 3-month HbA_{1c} or weight data;
 - started or stopped insulin;
 - increased or reduced number of oral hypoglycaemic agents (OHAs).

Results

- 2995 audit patients with follow-up data:
 - 640 (21.4%) on exenatide;
 - 323 (10.8%) on DPP-4 inhibitor;
 - 2032 (67.8%) on non-incretin-based diabetes treatment.

Baseline characteristics of patients starting on liraglutide in the ABCD nationwide liraglutide audit

	On exenatide (n=640)	On DPP-4 inhibitors (n=323)	Not on incretin medications (n=2032)	<i>p</i> -value
Gender (% male)	53.0	55.1	54.4	0.768
Ethnic (% Caucasian)	87.5	90.5	91.0	0.057
Age (years)	55.2 (11.1)	57.2 (11.7)	55.5 (10.9)	0.022
Diabetes duration (years)	10 (7–13)	8 (5–11)	9 (5–13)	< 0.001
HbA _{1c} (%)	9.12 (1.77)	9.41 (1.61)	9.38 (1.73)	0.004
Weight (kg)	107.3 (22.7)	107.4 (20.8)	111.9 (23.1)	< 0.001
BMI (kg/m²)	37.9 (7.0)	37.7 (6.5)	39.4 (7.7)	< 0.001
On insulin treatment (%)	38.8	13.3	46.7	< 0.001

Results for age, HbA_{1c}, weight and BMI quoted as mean (SD) and diabetes duration as median (interquartile range). BMI, body mass index.

- 64 were due to persistent GI side-effects;
- 22 were due to lack of HbA_{1c} or weight efficacy of exenatide BD;
- 45 preferred one injection or had problems with complying with two injections;
- 4 had non-GI side-effects to exenatide.
- 76 of 135 and 73 of 135 had HbA_{1c} and weight data available at 3 months.


3-month HbA_{1c} and weight changes, rates of GI side-effects and liraglutide discontinuation among patients switching exenatide to liraglutide

	GI side-effects (n=64)	Lack of efficacy (n=22)	Preference/ compliance (n=45)
n	36	13	27
Hb A_{1c} change (%)	-0.51 (0.23)	-0.47 (0.39)	-0.96 (0.26)
<i>p</i> -value	0.034	0.249	0.001
n	36	13	24
Weight change (kg)	-1.6 (0.4)	-0.4 (0.8)	-0.5 (0.8)
<i>p</i> -value	0.001	0.638	0.564
GI side-effects	8/64 (12.5%)	1/22 (4.5%)	6/45 (13.3%)
Liraglutide discontinuation	5/64 (7.8%)	2/22 (9.1%)	0/45 (0%)

Conclusions

- We provide data on the effects of switching exenatide BD or DPP-4 inhibitors to liraglutide 1.2 mg.
- While HbA_{1c} and weight reductions are clearly superior when liraglutide is used as add-on therapy, patients with problems with exenatide BD are able to obtain further HbA_{1c} and weight reductions when switched to liraglutide 1.2 mg.
- After exclusions, 1218 HbA_{1c} and 1235 weight data available for comparisons at 3 months.

3 month HbA_{1c} changes of patients switching exenatide BD or DPP-4 inhibitors to liraglutide 1.2 mg in comparison with liraglutide add-on therapy



- Patients with GI side-effects with exenatide BD, who had preference for one injection or had compliance issues obtained benefit.
- GI side-effects were lower and rates of discontinuation similar among patients switching from exenatide BD to liraglutide in comparison with other groups of patients.

Acknowledgement

• We thank all the nationwide audit contributors for submitting data on patients on liraglutide.

Disclosure

• The ABCD nationwide liraglutide audit programme has received grants from Novo Nordisk. This audit was independently initiated and performed by ABCD and the authors remained independent in the analysis and writing of this report.

